<DOC>
	<DOCNO>NCT01903460</DOCNO>
	<brief_summary>The study randomize , double-blind , placebo-controlled study evaluate safety tolerability LUM001 . Efficacy assess evaluate effect LUM001 versus placebo biochemical marker pruritus associate Alagille Syndrome .</brief_summary>
	<brief_title>Safety Efficacy Study LUM001 Treatment Cholestatic Liver Disease Patients With Alagille Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>1 . Diagnosis Alagille Syndrome 2 . Evidence cholestasis 3 . Moderate severe pruritus 4 . Ability understand willingness sign inform consent/assent prior initiation study procedures 1 . Surgical disruption enterohepatic circulation 2 . Liver transplant 3 . History presence concomitant liver disease 4 . Females pregnant lactate 5 . Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>